SCHEMBL4364518

SCHEMBL4364518

O=C(NC(Cc1ccc(OC(F)(F)F)cc1)C(=O)O)c1ccc(Oc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR2 P25090 2/20 0.55
GPR132 Q9UNW8 2/20 0.53
MAPK14 Q16539 1/20 0.53
TRPV1 Q8NER1 1/20 0.52
EPHX2 P34913 2/20 0.52
PPARG P37231 2/20 0.52
PPARA Q07869 1/20 0.52
CA2 P00918 2/20 0.50
KLKB1 P03952 1/20 0.49
MME P08473 1/20 0.49
ACE P12821 1/20 0.49
CPA1 P15085 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
PTPN1 P18031 1/20 0.49
PRSS1 P07477 1/20 0.48
PRSS2 P07478 1/20 0.48
PRSS3 P35030 1/20 0.48
USP30 Q70CQ3 1/20 0.48
ITGB3 P05106 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5926412 0.97 FPR2 (0.52) FPR2GPR132MAPK14TRPV1EPHX2
SCHEMBL5926235 0.93 FPR2 (0.55) FPR2GPR132TRPV1EPHX2PPARG
SCHEMBL5926737 0.93 FPR2 (0.55) FPR2GPR132TRPV1EPHX2PPARG
SCHEMBL4364758 0.91 CA2 (0.58) FPR2GPR132MAPK14EPHX2PPARG
SCHEMBL5926757 0.91 MAPK14 (0.55) FPR2GPR132MAPK14PPARGCA2
SCHEMBL5927112 0.91 MAPK14 (0.55) FPR2GPR132MAPK14PPARGCA2
SCHEMBL4368377 0.90 CA2 (0.57) FPR2GPR132MAPK14TRPV1EPHX2
SCHEMBL4364527 0.90 CA2 (0.63) FPR2GPR132TRPV1EPHX2PPARG
SCHEMBL4373687 0.90 TRPV1 (0.51) FPR2GPR132MAPK14TRPV1EPHX2
SCHEMBL5926551 0.89 MAPK14 (0.59) FPR2GPR132MAPK14PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344029-B2 Substituted propanamide derivative and pharmaceutical composition containing the same DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-01-01 US disclosed
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-11-26 US disclosed
EP-1908466-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME Daiichi Sankyo Company, Limited (JP) 2008-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090292024-A1 SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME PTMS, C1S, ACP3 FPR2 3587/4885GPR132 391/4885MAPK14 1716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.